This Question-and-Answer (Q&A) document covers commonly asked questions and answers on TB exams, treatment, and reimbursement through Social Health Insurance (SHI). It provides guidance to TB treatment facilities as they integrate SHI and transition TB treatment services into SHI. The document also includes hyperlinks as additional reference sources for readers.

This report presents findings from LHSS Vietnam's international review of diagnosis-related group contracts and provides a series of evaluations and recommendations.

This rapid assessment aimed to determine which health facilities in seven high-TB burden provinces of Vietnam meet social health insurance (SHI) requirements for TB service provision and for reimbursement of TB services through the SHI scheme.

This report provides a review of international experience to draw out practical and scientific approaches for both the Ministry of Health (MOH) and Vietnam Social Security (VSS) to consider. Conclusions and recommendations are provided.

Lhss prepared this report, discussing procurement and payment considerations related to the transition of first-line tuberculosis (TB) drug procurement in Vietnam from the central state budget to the social health insurance fund starting in 2022.

Conducted by LHSS, this market analysis examines four factors affecting SHI-covered ARV procurement and supply in Vietnam, and it also summarizes findings and recommendations across each of these factors.

This document provides a roadmap for Vietnam’s National Tuberculosis (TB) Program to transition procurement and payment for TB drugs to the country’s social health insurance scheme.

This report summarizes the results of a review of international experience and best practices related to pro-health excise taxes.

LHSS in this report recommends that the government raise pro-health excise taxes at greater rates than currently proposed by the Ministry of Finance in order to increase the revenue raised.